ReceptaBio

Recepta Biopharma is a Brazilian biotechnology company dedicated to the research and development of novel monoclonal antibodies and peptides for the treatment of cancer. Founded in 2006 through a strategic partnership with the Ludwig Cancer Research Institute, the company focuses on identifying tumor-specific targets and developing high-affinity biologics. Its pipeline features several humanized antibodies, including RebmAb100 (targeting Lewis Y antigen) and RebmAb200 (targeting NaPi2b), the latter of which was licensed to Mersana Therapeutics for development as an antibody-drug conjugate (Upifitamab Rilsodotin). ReceptaBio also advances immunomodulators targeting PD-1 and CTLA-4, alongside a portfolio of therapeutic peptides. By collaborating with leading Brazilian research institutions and international partners, the company aims to bring innovative and cost-effective oncology therapies to the global market.